By Daniella Parra
Recordati said it will acquire the global rights to Enjaymo, used to treat a rare blood disorder, from Sanofi.
Enjaymo has been approved by the FDA, European Commission, and Japan’s Ministry of Health, the company said.
Recordati said it will pay Sanofi $825 million upfront, with additional payments of up to $250 million tied to sales milestones.
“This transaction is in-line with our broader strategy, reaffirms our commitment to the Rare Diseases space and is complementary to our Oncology portfolio, specifically Sylvant. Enjaymo further expands our Rare Diseases footprint in the U.S., Japan and Europe, and will contribute positively to both our top and bottom lines,” said CEO Rob Koremans. “Most importantly, with a strong clinical profile and as the only product approved for the treatment of CAD, Enjaymo addresses a serious unmet medical need for patients living with this debilitating disease.”
Contact: